Amneal Pharmaceuticals, Inc. has launched bimatoprost ophthalmic solution 0.01% as its latest generic available to the U.S. commercial market.
Let’s take it from the top.
As a prostaglandin analog (PGA), Amneal’s generic version of bimatoprost ophthalmic solution 0.01% was granted FDA abbreviated new drug application (ANDA) approval in September 2025.
- Details on this approval pathway can be found here.
Its indication: For the reduction of elevated intraocular pressure (IOP) in patients diagnosed with open-angle glaucoma (OAG) or OHT.
And what do we know about bimatoprost specifically?
Available in varying concentrations, this active ingredient has an extensive history of use for various ocular applications. Check it out.
- For elevated IOP: The PGA’s mechanism of action includes increasing aqueous humor outflow throughout both the trabecular meshwork and uveoscleral routes.
Also, in other clinical news, bimatoprost is involved in:
- Nicox’s investigational nitric oxide (NO)-donating bimatoprost formulation for IOP reduction
- SpyGlass Pharma’s investigational sustained-release delivery system for glaucoma and OHG
Noted. Next up: the name-brand version of this generic.
That would be the FDA-approved (in 2010) LUMIGAN (bimatoprost ophthalmic solution) 0.01% by Allergan, Inc., an AbbVie company.
Talk dosing.
Per LUMIGAN’s prescribing information (PI): One drop of the bimatoprost formulation should be administered in the affected eye(s) once daily in the evening.
A couple of notes:
- The drop shouldn’t be administered more than once daily, as “more frequent administration of (PGAs) may decrease the (IOP) lowering effect:
- Drop use isn’t recommended for patients under the age of 16 due to a potential safety risk for increased pigmentation (associated with long-term chronic use)
Does this generic have its own PI to refer to?
It does—see here.
Also, check out its generic product details here.
Speaking of use … any other precautions to consider?
Check out our rundown on:
- Contraindications
- Warnings and precautions
- Drop use for contact lens wearers
- Potential adverse reactions (including post-marketing reports)
Also duly noted. So … where will this be available for purchase?
No word yet on that front … reach out to Amneal for details on availability and pricing.
(And see the company’s entire generic portfolio here.)